Munemura M, Agui T, Sibley D R
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland 20892.
Endocrinology. 1989 Jan;124(1):346-55. doi: 10.1210/endo-124-1-346.
The effect of chronic estrogen treatment on the anterior pituitary D2 dopamine receptor was studied by treating rats with diethylstilbestrol (DES) over a 6-week period. DES treatment resulted in an increase in anterior pituitary weight and PRL content and serum PRL levels compared to those in sham-treated controls. The status of the anterior pituitary D2 dopamine receptor was evaluated using both radioligand binding and adenylate cyclase assays. [125I]N-(p-aminophenethyl)spiroperidol [( 125I]NAPS), a derivative of the D2-selective antagonist spiperone, was used to quantitate D2 receptors. Saturation analysis of [125I]NAPS binding indicated that DES treatment had no effect on the affinity or maximum binding capacity of the radioligand for the D2 receptor. Competition analysis with unlabeled D2 antagonists for [125I]NAPS binding also indicated that DES treatment did not affect antagonist interactions with the receptor. In contrast, the interactions of agonists with the D2 receptors from DES-treated rats were modified, as assessed through [125I]NAPS competition analysis. Using control tissue, agonist competition curves revealed both high and low affinity agonist binding states of the receptor. In the presence of guanine nucleotides, the high affinity agonist binding state is abolished, reflecting coupling of the receptor with a guanine nucleotide regulatory (G) protein. In DES-treated tissue, agonist competition curves indicated the presence of only low affinity agonist binding, with minimal effects of guanine nucleotides, suggesting uncoupling of receptor-G-protein interactions. The functionality of the D2 receptor was further assessed by examining dopaminergic inhibition of vasoactive intestinal peptide-stimulated adenylate cyclase activity. Although DES treatment resulted in a reduction of vasoactive intestinal peptide-stimulated enzyme activity itself, the ability of dopaminergic agonists to inhibit this activity was reduced by about 50%. These results suggest that estrogen is capable of attenuating the functional coupling of the D2 receptor with its biochemical effector system in the anterior pituitary gland.
通过用己烯雌酚(DES)对大鼠进行为期6周的治疗,研究了慢性雌激素治疗对垂体前叶D2多巴胺受体的影响。与假手术对照组相比,DES治疗导致垂体前叶重量、PRL含量和血清PRL水平增加。使用放射性配体结合和腺苷酸环化酶测定法评估垂体前叶D2多巴胺受体的状态。[125I]N-(对氨基苯乙基)螺哌啶醇[(125I]NAPS),一种D2选择性拮抗剂螺哌酮的衍生物,用于定量D2受体。[125I]NAPS结合的饱和分析表明,DES治疗对放射性配体与D2受体的亲和力或最大结合容量没有影响。用未标记的D2拮抗剂对[125I]NAPS结合进行竞争分析也表明,DES治疗不影响拮抗剂与受体的相互作用。相反,通过[125I]NAPS竞争分析评估,DES处理大鼠的激动剂与D2受体的相互作用发生了改变。使用对照组织,激动剂竞争曲线显示了受体的高亲和力和低亲和力激动剂结合状态。在鸟嘌呤核苷酸存在下,高亲和力激动剂结合状态被消除,反映了受体与鸟嘌呤核苷酸调节(G)蛋白的偶联。在DES处理的组织中,激动剂竞争曲线表明仅存在低亲和力激动剂结合,鸟嘌呤核苷酸的影响最小,表明受体-G蛋白相互作用解偶联。通过检查多巴胺能对血管活性肠肽刺激的腺苷酸环化酶活性的抑制作用,进一步评估了D2受体的功能。虽然DES治疗导致血管活性肠肽刺激的酶活性本身降低,但多巴胺能激动剂抑制该活性的能力降低了约50%。这些结果表明,雌激素能够减弱D2受体与其在垂体前叶生化效应系统的功能偶联。